You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-1 antibody

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Sarcoma Trial in Shanghai (MASCT-I,PD1 Antibody,Apatinib)

Active, not recruiting
  • Sarcoma
  • MASCT-I,PD1 Antibody,Apatinib
  • Shanghai, Shanghai, China
    Shanghai Sixth People's Hospital
Nov 22, 2022

PD-1 Antibody, DC-Cell, NK-Cell Trial (Pembrolizumab, Nivolumab, Sintilimab)

Not yet recruiting
  • PD-1 Antibody
  • +3 more
  • (no location specified)
Jul 14, 2022

TNBC - Triple-Negative Breast Cancer Trial in Beijing (Eribulin, anti-PD-1 antibody)

Recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Beijing, Beijing, China
    The Fifth Medical Center of PLA General Hospital
May 29, 2022

Locally Advanced, NSCLC Trial in Shanghai (drug, procedure, radiation)

Recruiting
  • Locally Advanced
  • Non-small Cell Lung Cancer
  • Shanghai, China
    Shanghai Pulmonary Hospital
Mar 14, 2023

Hemophagocytic Lymphohistiocytosis Trial in Beijing (L-DEP and PD-1 antibody)

Not yet recruiting
  • Hemophagocytic Lymphohistiocytosis
  • L-DEP and PD-1 antibody
  • Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Apr 19, 2022

Hemophagocytic Lymphohistiocytosis Trial in Beijing (DEP combine with PD-1 antibody)

Recruiting
  • Hemophagocytic Lymphohistiocytosis
  • DEP combine with PD-1 antibody
  • Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Feb 13, 2022

Hepatocellular Carcinoma Trial in Beijing (Sintilimab, Lenvatinib, radiotherapy)

Recruiting
  • Hepatocellular Carcinoma
  • Beijing, Beijing, China
    Beijing Tsinghua Changgung Hospital
Jan 5, 2023

Relapsed or Refractory DLBCL Trial (Anti-PD-1 Antibody Plus Chidamide and Rituximab)

Not yet recruiting
  • Relapsed or Refractory DLBCL
  • Anti-PD-1 Antibody Plus Chidamide and Rituximab
  • (no location specified)
Apr 6, 2022

Cervical Cancer Trial in Amsterdam (Anti-PD-1 antibody balstilimab)

Not yet recruiting
  • Cervical Cancer
  • Anti-PD-1 antibody balstilimab
  • Amsterdam, Netherlands
    Amsterdam UMC
Oct 17, 2023

NSCLC Trial in Saint Petersburg, Cremona, Vilnius (REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab)

Terminated
Has Results
  • Non-small Cell Lung Cancer
  • Saint Petersburg, Florida
  • +2 more
Oct 22, 2022

Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1

Recruiting
  • Colorectal Neoplasms
  • long course radiotherapy + capecitabine + PD-1 monoclonal antibody
  • Beijing, Beijing, China
    Beijing Friendship Hospital
May 5, 2022

Chronic Hepatitis b, Anti-PD-1 Antibody, Peg-IFNa Trial in Chongqing (Anti-PD-1 antibody, NAs, Peg-IFNa)

Not yet recruiting
  • Chronic Hepatitis b
  • +2 more
  • Anti-PD-1 antibody
  • +2 more
  • Chongqing, Chongqing, China
    The 2nd affiliated Hospital of Chongqing Medical University
Mar 14, 2023

Chronic Hepatitis b, Anti-PD-1 Antibody Trial in Chongqing (Anti-PD-1 antibody, NAs)

Not yet recruiting
  • Chronic Hepatitis b
  • Anti-PD-1 Antibody
  • Anti-PD-1 antibody
  • NAs
  • Chongqing, Chongqing, China
    The 2nd affiliated Hospital of Chongqing Medical University
Mar 3, 2023

Leptomeningeal Disease Trial in Germany (Nivolumab [Opdivo])

Recruiting
  • Leptomeningeal Disease
  • Nivolumab [Opdivo]
  • Freiburg, Germany
  • +6 more
Nov 2, 2022

NSCLC Trial in Zhengzhou (L-TIL, Tislelizumab, Docetaxel)

Recruiting
  • Non-small Cell Lung Cancer
  • L-TIL, Tislelizumab, Docetaxel
  • Zhengzhou, Henan, China
    No.127 Dongming Road
May 17, 2023

Basal Cell Carcinoma Trial in Zürich (Cemiplimab Injection [Libtayo])

Recruiting
  • Basal Cell Carcinoma
  • Cemiplimab Injection [Libtayo]
  • Zürich, Switzerland
    University Hospital Zurich, Clinic of Dermatology
Nov 3, 2022

Advanced Melanoma Trial in Zhengzhou (Tislelizumab Injection)

Not yet recruiting
  • Advanced Melanoma
  • Tislelizumab Injection
  • Zhengzhou, Henan, China
    Department of Bone and Soft Tissue ,Henan Cancer Hospital
Aug 4, 2022

Advanced Malignant Tumors Trial in China (LBL-019 Injection, anti-PD-1 antibody injection)

Recruiting
  • Advanced Malignant Tumors
  • LBL-019 Injection
  • anti-PD-1 antibody injection
  • Wuhan, Hubei, China
  • +4 more
Apr 26, 2022

Hepatocellular Carcinoma Trial in Shanghai (Sintilimab, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • Shanghai, China
    Fudan University Shanghai Cancer Center
May 30, 2022

Objective Response Rate Trial in Wuhan (GM-CSF)

Recruiting
  • Objective Response Rate
  • Wuhan, Hubei, China
    Renmin Hospital of Wuhan University
Feb 25, 2023

Nasopharyngeal Tumors Trial in China (Sintilimab, Gemcitabine, Cisplatin)

Active, not recruiting
  • Nasopharyngeal Neoplasms
  • Foshan, Guangdong, China
  • +8 more
Oct 6, 2022

Intrahepatic Cholangiocarcinoma Trial in Shanghai (Camrelizumab, US/CT-guided Percutaneous Cryoablation)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 1, 2022

PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

Recruiting
  • Immune Checkpoint Inhibitors
  • +9 more
  • Radiotherapy for targeted lesions and PD-1 antibody
  • Beijing, Beijing, China
    Lei Li
Apr 1, 2022

Non Small Cell Lung Cancer, Solid Tumors, Adult, Endometrial Cancer Trial in Fairfax (TNG260, Pembrolizumab)

Recruiting
  • Non Small Cell Lung Cancer
  • +6 more
  • Fairfax, Virginia
    NEXT Oncology
Jun 7, 2023

Anti-PD-1 Antibody Combined With Chemotherapy for Neoadjuvant

Active, not recruiting
  • Locally Advanced Gastric Adenocarcinoma
  • PD-1
  • DNA panel and RNA Sequencing
  • Xi'an, Shaanxi, China
    Xijing Hospital of Digestive Diseases
Aug 17, 2022